MA21667A1 - Procede pour augmenter l'hemoglobine foetale par tar traitement avec de l'activine et/ou de l'inhibine . - Google Patents

Procede pour augmenter l'hemoglobine foetale par tar traitement avec de l'activine et/ou de l'inhibine .

Info

Publication number
MA21667A1
MA21667A1 MA21919A MA21919A MA21667A1 MA 21667 A1 MA21667 A1 MA 21667A1 MA 21919 A MA21919 A MA 21919A MA 21919 A MA21919 A MA 21919A MA 21667 A1 MA21667 A1 MA 21667A1
Authority
MA
Morocco
Prior art keywords
inhibin
activin
beta
fetal hemoglobin
globin
Prior art date
Application number
MA21919A
Other languages
English (en)
Original Assignee
Norbert Albers
Susan P Perrine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norbert Albers, Susan P Perrine filed Critical Norbert Albers
Publication of MA21667A1 publication Critical patent/MA21667A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA21919A 1988-11-01 1989-10-31 Procede pour augmenter l'hemoglobine foetale par tar traitement avec de l'activine et/ou de l'inhibine . MA21667A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/266,421 US4997815A (en) 1988-11-01 1988-11-01 Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin

Publications (1)

Publication Number Publication Date
MA21667A1 true MA21667A1 (fr) 1990-07-01

Family

ID=23014518

Family Applications (1)

Application Number Title Priority Date Filing Date
MA21919A MA21667A1 (fr) 1988-11-01 1989-10-31 Procede pour augmenter l'hemoglobine foetale par tar traitement avec de l'activine et/ou de l'inhibine .

Country Status (9)

Country Link
US (1) US4997815A (fr)
EP (2) EP0617966A1 (fr)
JP (1) JPH02256622A (fr)
AT (1) ATE119396T1 (fr)
CA (1) CA2001897A1 (fr)
DE (1) DE68921546T2 (fr)
IL (1) IL92167A (fr)
MA (1) MA21667A1 (fr)
PT (1) PT92174B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03173805A (ja) * 1989-09-11 1991-07-29 Ajinomoto Co Inc 卵分割促進剤
US5166190A (en) * 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
US5102868A (en) * 1990-01-08 1992-04-07 Genentech, Inc. Method for inhibiting follicular maturation
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof
EP0515494A1 (fr) * 1990-02-15 1992-12-02 Chiron Corporation Utilisation de inhibiteur de l'activite des cytokines
WO1992004913A1 (fr) * 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Procede d'augmentation de la production de globules rouges par traitement a l'aide d'activine ou de peptides apparentes a l'activine
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
US5487895A (en) * 1993-08-13 1996-01-30 Vitaphore Corporation Method for forming controlled release polymeric substrate
EP0664699A1 (fr) * 1993-08-13 1995-08-02 Vitaphore Corporation Systemes de liberation de medicament contenant des microspheres a base d'hydrogel
RO115498B1 (ro) * 1993-10-29 2000-03-30 Univ Boston Metoda de tratament a neoplasmului
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
JP2001527517A (ja) 1996-07-26 2001-12-25 スーザン・ピー・ペリーネ 血液、ウイルス性および細胞性疾患の治療組成物
AUPO638897A0 (en) * 1997-04-23 1997-05-22 Monash University Modulation of cell growth and methods relating thereto
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
US20060003446A1 (en) * 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
AU2012203441B2 (en) * 2002-05-17 2015-01-29 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
JP2006513727A (ja) * 2002-05-17 2006-04-27 マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー 中胚葉および成体型内胚葉細胞集団
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1608628A2 (fr) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
CA2575370A1 (fr) * 2004-08-10 2006-02-23 Voyager Pharmaceutical Corporation Procedes de traitement des nourrissons prematures
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006122319A2 (fr) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
EP1976835A2 (fr) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Inhibiteurs des histone desacetylases
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2010105112A1 (fr) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Détection d'acides gras à chaîne courte dans des échantillons biologiques
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
EP2509418A4 (fr) 2009-12-08 2013-03-20 Hemaquest Pharmaceuticals Inc Procédés et régimes à faible dose pour traiter des troubles des globules rouges
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
WO2013119800A1 (fr) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Utilisation d'antagonistes de ghréline ou de récepteur de ghréline pour prévenir ou traiter une maladie psychiatrique sensible au stress
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US20160106821A1 (en) * 2014-10-20 2016-04-21 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (fr) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Utilisation de ghréline ou d'agonistes fonctionnels des récepteurs de la ghréline pour prévenir et traiter une maladie psychiatrique sensible au stress
KR20220034736A (ko) 2019-05-31 2022-03-18 비락타 서브시디어리 인크. 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0730114B2 (ja) * 1985-04-03 1995-04-05 正雄 五十嵐 インヒビン
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
NZ231899A (en) * 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4822821A (en) * 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
AU610858B2 (en) * 1987-01-29 1991-05-30 Inhibin Pty Limited Isolation of single chain proteins with fsh suppressing activity from follicular fluid
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5032507A (en) * 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis

Also Published As

Publication number Publication date
PT92174A (pt) 1990-05-31
DE68921546D1 (de) 1995-04-13
EP0367590B1 (fr) 1995-03-08
DE68921546T2 (de) 1995-07-06
PT92174B (pt) 1995-09-12
EP0367590A3 (fr) 1992-01-02
CA2001897A1 (fr) 1990-05-01
JPH02256622A (ja) 1990-10-17
EP0617966A1 (fr) 1994-10-05
IL92167A0 (en) 1990-07-12
ATE119396T1 (de) 1995-03-15
US4997815A (en) 1991-03-05
IL92167A (en) 1994-07-31
EP0367590A2 (fr) 1990-05-09

Similar Documents

Publication Publication Date Title
MA21667A1 (fr) Procede pour augmenter l'hemoglobine foetale par tar traitement avec de l'activine et/ou de l'inhibine .
PT96518A (pt) Processo para a preparacao de produtos de adicao de complexos de renio ou de tecnecio-99m e de uma dioxima e de um acido boronico,comportando um grupo bioquimicamente activo, com accao terapeutica ou de diagnostico e de novos compostos intermedios utilizados na sua preparacao
EP1014996A4 (fr) Compositions de saccharide et methodes de traitement specifiques de la maladie d'alzheimer et d'autres amyloidoses
ATE156704T1 (de) Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
ATE143261T1 (de) Zusammensetzung zur behandlung entzündlicher darmerkrankungen
PT87996A (pt) Processo para a preparacao de composicoes farmaceuticas uteis para a correccao de anormalidades em complexos imunologicos de circulacao e na funcao dos monocitos contendo arn de dupla cadeia
BR8704328A (pt) Compostos,processo para sua preparacao,utilizacao,composicoes fungicidas e processo para combater doencas fungicidas em culturas
EP0307566A3 (en) Method for analysing the crystalline morphology of blood or urine for an early diagnosis and for producing medicines
BE858356A (fr) Derives d'acide 7-acylamino-8-oxo-3-oxa-1-azabicyclo-(4.2.0)octane-2-carboxylique, leur procede de preparation et leur application en therapeutique
TNSN90103A1 (fr) Procede pour augmenter l'hemoglobine foetale par traitement avec de l'activine et/ou de l'inhibine
Guillard et al. Comparison of the anti-inflammatory activity of sodium acexamate and zinc acexamate in healing skin wounds in rabbits
ATE110277T1 (de) Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.
KR880002525A (ko) 뇌 허혈성 병을 수반하는 질환 치료제
Bach Lonazolac-Ca(Irritren), a new non-steroidal antirheumatic agent. Clinical data based on 18, 000 treated patients.
RU93003597A (ru) Способ лечения свежеперенесенного травматического повреждения головного мозга
Moon et al. Clinical Study of Kienbock's Disease
DS Sexual dysfunctions in the male
王小马 et al. THE EFFECT OF ACUPUNCTURE IN 90 CASES OF SEQUELAE OF BRAIN CONCUSSION
Kim et al. A Study of Influencing Factors Causing Peripheral Vascular Occlusions in Diabetes Mellitus Patients by Doppler Flow Meter
Fang A mathematical model for burn patients.
RU93036990A (ru) Способ лечения острых воспалительных заболеваний матки
van Rijckevorsel-Harmant et al. Intravenous immunoglobulins in the treatment of intractable epilepsy
Lee et al. A Clinical Study of Transient Synovitis of the Hip Joint
FR2700337B1 (fr) Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
Madden et al. Outpatient behavior therapy and biofeedback treatment of pain and related problems.